Morrison et al. found that mTORC2 signaling drives AKT-dependent tumor progression in HER2-amplified breast cancer, and mTORC1/2 dual kinase inhibitors reduce the survival of AKT-dependent HER2-amplified cells [85]. The gene discussed is ERBB2; the disease is breast cancer.